Travelling with a protocol

Two agencies, two entirely different questions, and almost every guide on the internet answers one and reports it as the other. Sort that out and travelling gets a great deal simpler.

Last updated 22 August 2026

Screening, storage and the border, kept apart

PC-ART-003 Reference 22 August 2026 8 min read

A small insulated cooler bag open on a hotel desk, holding two capped vials upright in foam beside a flat gel pack. — The end of the journey. Most of what goes wrong with a travelling vial happens long before this point, and to temperature rather than to security.

Two agencies, two questions

Travelling with a protocol is far more manageable than the forums suggest, and it gets simpler the moment you split one question into two. "Will security let this through" and "is this lawful to carry into the country I am entering" are decided by different bodies with different jobs. Screening authorities look for threats to aviation and say so plainly. Whether a substance may lawfully be imported belongs to the drug regulator and the customs service of wherever you land.

Collapse the two and you get errors pointing in opposite directions. Clearing a checkpoint feels like an answer to a question the checkpoint never asked. Meanwhile a rule that genuinely bites at a border gets written up in the language of screening, as though the verdict travelled along with the bag.

Airport screening

Decides whether an item may pass the checkpoint onto an aircraft. Publishes per-item pages, each with its own last-updated date.

Medically necessary liquids are exempt from the 3.4-ounce rule
Gel ice packs are permitted regardless of physical state
The final decision rests with the officer, on every item page

Import and customs

Decides whether a substance may lawfully enter a country. Nothing about a cleared checkpoint speaks to this.

Each destination applies its own rule
A prescription has no legal standing outside the country that issued it
Research use only is a seller's label, not a legal category

What the screening pages actually say

The good news is that the screening rules are published, specific, and more generous than most people expect. TSA exempts medically necessary liquids from the 3-1-1 rule with three conditions in the same sentence: medically necessary, a quantity reasonable for the trip, and declared. Unused syringes are permitted when they accompany the injectable medication they are for, and TSA's wording adds that they be declared for inspection. Gel ice packs and freezer packs are permitted for medically necessary liquids whether they are frozen, melted or slushy.

Two details get dropped every time that paragraph is repeated. The first is the standing line on every item page: the final decision rests with the officer at the checkpoint. Following the procedure improves your odds and does not create an entitlement — TSA Cares says outright that a medically necessary liquid whose alarm cannot be resolved may not be allowed through.

The second is what "medically necessary" is quietly doing. It is the word the whole exemption turns on. A prescribed, pharmacy-labelled medicine is the case it plainly covers. Material sold as research use only, carried without a prescription, is the case it plainly does not — and asserting medical necessity to a federal officer is a statement of fact, not a useful form of words.

One popular instruction runs backwards, and this is the easiest win of the whole trip. Keeping everything sealed in one case gets passed around as good practice; TSA asks for the opposite at the checkpoint, which is to take medically necessary items out of the carry-on and put them in a bin. Fly with a cooled case, by all means. Just open it when you reach the belt.

An open insulated pouch lying in a grey airport security tray on a conveyor belt, vials and a gel pack visible inside. — Out of the bag and into a bin. That is what the screening guidance actually asks for, and the opposite of the sealed-case advice doing the rounds.

The temperature rules are on the label

Here is where travel gets easier rather than harder, because the real storage windows are wider than the flat "2 to 8 °C at all times" rule everyone quotes. After first use, a semaglutide pen may be stored for 56 days at controlled room temperature between 15 and 30 °C, or refrigerated. Tirzepatide may be stored at up to 30 °C for 21 days. Those are the licensed in-use conditions, printed in the label's storage section. A stricter rule invented on top of them is not caution — it is a different rule with nobody's name on it.

Dried peptide is looser still, and honestly so. NIBSC describes dry peptides as stable at room temperature for days to weeks, recommends 4 °C or colder, and puts long-term storage at −20 °C. That is a range with an order of magnitude inside it, not the tidy one-to-two-week figure that circulates, and no source establishes the tidy one.

The chemistry underneath is worth knowing, partly because it is elegant and partly because the usual shorthand invents a mechanism that does not exist. Heat drives deamidation — an asparagine or glutamine side-chain amide hydrolysing to a carboxylic acid by way of a succinimide intermediate — and oxidation, mostly at methionine. Water is a reactant in both, which is exactly why a reconstituted vial ages faster than a dry one. Nothing here shatters or shears, and domestic freezing does not break covalent bonds. Freeze damage to proteins comes from three stresses: low temperature itself, freeze-concentration of solutes, and the ice-water interface — with ice formation the dominant destabiliser in at least one controlled study.

In-use storage, as printed on approved labels

4 categories · 4 compounds

Product	Record	Licensed in-use window	What the label does not say
Semaglutide pen, after first use	Semaglutide	56 days at 15–30 °C, or refrigerated at 2–8 °C	Nothing about a 25 °C ceiling — that threshold has no source
Tirzepatide, after first use	Tirzepatide	21 days at up to 30 °C	Nothing permitting freezing; the do-not-freeze instruction is real
Bacteriostatic water for injection		0.9% or 1.1% benzyl alcohol, per the USP monograph product	No 28-day statement appears anywhere in the label text
Lyophilised research peptide	BPC-157, Ipamorelin	Days to weeks at room temperature, per NIBSC; −20 °C long term	Any single figure — the published range spans an order of magnitude

Where the 28 days comes from

The 28-day figure is real, and tracing it back is genuinely satisfying, because it does not come from bacteriostatic water and it is not a shelf life. The FDA label for Bacteriostatic Water for Injection contains no 28-day statement anywhere. Twenty-eight days is the default beyond-use date USP <797> assigns to a preserved multiple-dose container once it has been entered or punctured, unless the manufacturer specifies otherwise.

Three things fall out of that sentence, and each one goes missing somewhere in the retellings. The clock starts at first puncture, not at reconstitution. It is a microbiological limit — it says how long the preservative can be relied on against contamination introduced by repeated entry, and nothing whatsoever about whether the peptide is still intact. And it yields to a manufacturer-specified date: several approved products carry in-use windows shorter than 28 days, so treat the figure as a ceiling rather than a constant.

The BAC-water calculator on this site applies 28 days from first puncture, refrigerated. That is the default, and the default is what the record says when nothing more specific exists.

A soft insulated bag stowed in the footwell under an aircraft seat, the cabin aisle out of focus behind it. — Carry-on rather than checked — for do-not-freeze instructions and for not being separated from your medication, not because of a screening rule that does not exist.

Cargo hold, and the rule nobody publishes

"Never pack peptides in checked luggage" is repeated as a rule by a great deal of travel advice and by no authority at all. TSA lists liquid medications and unused syringes as permitted in checked bags. There are two genuinely good arguments for taking them into the cabin, and both beat the invented rule: manufacturer instructions not to freeze the product, and the ordinary misery of being separated from your medication when a bag goes wandering.

The hold-temperature claim deserves the same care. Baggage holds on passenger aircraft are heated and pressurised; the case for extremes is stronger during long waits on the ground than at cruise. Where freezing does happen, the damage comes from ice formation and freeze-concentration, which is a real risk to a formulated protein and not the bond-shattering event the phrase implies.

Crossing a border is a separate decision

The border is the one place to slow down, and the rule is simple enough to carry in your head: every destination applies its own import law, and a pharmacy label from one country has no legal standing in another. Semaglutide and tirzepatide are prescription-only medicines rather than controlled substances in the United States, the United Kingdom and Australia, which is why a labelled, prescribed product is the straightforward case. That is narrower and more checkable than any claim about a universal medical defence, and it is what the sources actually support.

Research-use material is a different kind of thing entirely. "Research use only" is a labelling convention used by sellers, not a legal category authorising human use — in US regulation the phrase belongs to in vitro diagnostic products, and intended use governs the rest. No border agency publishes a seizure rate for research peptides, so anyone quoting you a risk level is quoting nothing.

One last claim, and we would be the beneficiary of it, so we will name it ourselves. A reference database cannot tell you whether the vial in your bag has degraded or been contaminated. Those are properties of one physical vial, established by assaying that vial. The corpus can tell you what the record says about a compound. It cannot tell you what is in your luggage.

Beyond-use date: The date after which a compounded or entered preparation should not be used. Set from first puncture for a preserved multiple-dose container, defaulting to 28 days unless the manufacturer specifies otherwise.
Bacteriostatic water: Sterile water containing benzyl alcohol as a preservative, supplied at 0.9% or 1.1% under the USP monograph.
Deamidation: Hydrolysis of an asparagine or glutamine side-chain amide to a carboxylic acid, via a succinimide intermediate. Accelerated by temperature and pH. The covalent change is irreversible; whether activity changes is site-dependent.
Thermolabile: Readily altered by moderate heat. A property of a particular sequence and formulation, not of peptides as a class — two approved peptide products are licensed for weeks at up to 30 °C.
Cold chain: A temperature-controlled handling and storage path, conventionally 2 to 8 °C. Standard for distribution; not a universal requirement in use.
3-1-1 exemption: The screening carve-out for medically necessary liquids from the standard container-size limit, conditional on necessity, reasonable quantity, and declaration.

Sources and evidence

15 sources

Transportation Security Administration. TSA Cares — Disabilities and Medical ConditionsGovernment guidance

How this source supports the article

The 3-1-1 exemption for medically necessary liquids and its three conditions; the instruction to inform the officer before screening begins; the instruction to remove medically necessary items into a bin; and the statement that an unresolvable alarm may mean the item is not allowed.

Limitations

Guidance rather than regulation, revised without notice, and applicable only to screening in the United States. It settles nothing about whether an item may lawfully be carried or imported.